Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26]

EY Yu; JM Piulats; G Gravis; PCC Fong; T Todenhofer; B Laguerre; JA Arranz; S Oudard; C Massard; J Heinzelbecker; LT Nordquist; J Carles; MP Kolinsky; Marinela Augustin; H Gurney; A Tafreshi; XT Li; P Qiu; CH Poehlein; C Schloss; JS de Bono

doi:10.1016/j.eururo.2022.11.025

Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26]

EY Yu, JM Piulats, G Gravis, PCC Fong, T Todenhofer, B Laguerre, JA Arranz, S Oudard, C Massard, J Heinzelbecker, LT Nordquist, J Carles, MP Kolinsky, Marinela Augustin (Co-author), H Gurney, A Tafreshi, XT Li, P Qiu, CH Poehlein, C SchlossJS de Bono

Department of Internal Medicine V, Division of Oncology and Hematology

Research output: Contribution to journal › Correction › peer-review

3 Citations (Web of Science)

Original language	English
Pages (from-to)	e87
Journal	EUROPEAN UROLOGY
Volume	83
Issue number	3
DOIs	https://doi.org/10.1016/j.eururo.2022.11.025
Publication status	Published - Mar 2023

Access to Document

10.1016/j.eururo.2022.11.025

3 Citations
1 Original Article

Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study
Yu, E., Piulats, J., Gravis, G., Fong, P., Todenhofer, T., Laguerre, B., Arranz, J., Oudard, S., Massard, C., Heinzelbecker, J., Nordquist, L., Carles, J., Kolinsky, M., Augustin, M. (Co-author), Gurney, H., Tafreshi, A., Li, X., Qiu, P., Poehlein, C. & Schloss, C. & 1 others, de Bono, J., Jan 2023, In: EUROPEAN UROLOGY . 83, 1, p. 15-26 12 p.
Research output: Contribution to journal › Original Article › peer-review
50 Citations (Web of Science)

Cite this

Yu, EY., Piulats, JM., Gravis, G., Fong, PCC., Todenhofer, T., Laguerre, B., Arranz, JA., Oudard, S., Massard, C., Heinzelbecker, J., Nordquist, LT., Carles, J., Kolinsky, MP., Augustin, M., Gurney, H., Tafreshi, A., Li, XT., Qiu, P., Poehlein, CH., ... de Bono, JS. (2023). Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26]. EUROPEAN UROLOGY , 83(3), e87. https://doi.org/10.1016/j.eururo.2022.11.025

Yu, EY ; Piulats, JM ; Gravis, G et al. / Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer : Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26]. In: EUROPEAN UROLOGY 2023 ; Vol. 83, No. 3. pp. e87.

@article{cbc781f1645a46b2a82f3a103b0b3813,

title = "Corrigendum to {"}Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study{"} [Eur Urol 83 (2023) 15-26]",

author = "EY Yu and JM Piulats and G Gravis and PCC Fong and T Todenhofer and B Laguerre and JA Arranz and S Oudard and C Massard and J Heinzelbecker and LT Nordquist and J Carles and MP Kolinsky and Marinela Augustin and H Gurney and A Tafreshi and XT Li and P Qiu and CH Poehlein and C Schloss and \{de Bono\}, JS",

note = "Augustin: Paracelsus Medical University, Nuremberg, Germany",

year = "2023",

month = mar,

doi = "10.1016/j.eururo.2022.11.025",

language = "English",

volume = "83",

pages = "e87",

journal = "EUROPEAN UROLOGY ",

issn = "0302-2838",

publisher = "Elsevier ",

number = "3",

}

Yu, EY, Piulats, JM, Gravis, G, Fong, PCC, Todenhofer, T, Laguerre, B, Arranz, JA, Oudard, S, Massard, C, Heinzelbecker, J, Nordquist, LT, Carles, J, Kolinsky, MP, Augustin, M, Gurney, H, Tafreshi, A, Li, XT, Qiu, P, Poehlein, CH, Schloss, C & de Bono, JS 2023, 'Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26]', EUROPEAN UROLOGY , vol. 83, no. 3, pp. e87. https://doi.org/10.1016/j.eururo.2022.11.025

Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26]. / Yu, EY; Piulats, JM; Gravis, G et al.
In: EUROPEAN UROLOGY , Vol. 83, No. 3, 03.2023, p. e87.

Research output: Contribution to journal › Correction › peer-review

TY - JOUR

T1 - Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer

T2 - Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26]

AU - Yu, EY

AU - Piulats, JM

AU - Gravis, G

AU - Fong, PCC

AU - Todenhofer, T

AU - Laguerre, B

AU - Arranz, JA

AU - Oudard, S

AU - Massard, C

AU - Heinzelbecker, J

AU - Nordquist, LT

AU - Carles, J

AU - Kolinsky, MP

AU - Augustin, Marinela

AU - Gurney, H

AU - Tafreshi, A

AU - Li, XT

AU - Qiu, P

AU - Poehlein, CH

AU - Schloss, C

AU - de Bono, JS

N1 - Augustin: Paracelsus Medical University, Nuremberg, Germany

PY - 2023/3

Y1 - 2023/3

U2 - 10.1016/j.eururo.2022.11.025

DO - 10.1016/j.eururo.2022.11.025

M3 - Correction

C2 - 36528479

SN - 0302-2838

VL - 83

SP - e87

JO - EUROPEAN UROLOGY

JF - EUROPEAN UROLOGY

IS - 3

ER -

Yu EY, Piulats JM, Gravis G, Fong PCC, Todenhofer T, Laguerre B et al. Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26]. EUROPEAN UROLOGY . 2023 Mar;83(3):e87. doi: 10.1016/j.eururo.2022.11.025